Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors by Zixi Wu, Junbiao Zhang, Le Li, Zhihua Wang, Chunguang Yang

Subjects: Get full text

Inhibiting HnRNP L-mediated alternative splicing of EIF4G1 counteracts immune checkpoint blockade resistance in Castration-resistant prostate Cancer by Xumin Zhou, Shilong Cheng, Zhongjie Chen, Jinming Zhang, Jiaqi Wang, Qiang Li, Xumin Zhou

Subjects: Get full text

The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC by Yifan Wang, Yifan Wang, Jianying Zhou, Simin Peng, Simin Peng, Zhao Cui, Zhao Cui, Weiqi Wang, Weiqi Wang, Wenqin Zeng, Wenqin Zeng, Tingting Qiu, Zhentian Liu

Subjects: Get full text

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence by Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida, Tatsuki Ikoma, Yuki Takeyasu, Utae Katsushima, Hiroshige Yoshioka, Takayasu Kurata

Subjects: Get full text

Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report by Tomoyuki Otsuka, Yoshiki Kojitani, Fumio Imamura, Junko Fukutake, Minako Nishio, Takashi Fujii, Toshihiro Kudo

Subjects: “…immune checkpoint inhibitor…”
Get full text

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison by Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii

Subjects: Get full text

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) by Stefania Angelicola, Francesca Giunchi, Francesca Ruzzi, Mariateresa Frascino, Mary Pitzalis, Laura Scalambra, Maria Sofia Semprini, Olga Maria Pittino, Chiara Cappello, Irene Siracusa, Ilaria Candida Chillico, Martina Di Noia, Cristian Turato, Silvia De Siervi, Francesco Lescai, Teresa Ciavattini, Giulia Lopatriello, Luca Bertoli, Hugo De Jonge, Luisa Iamele, Annalisa Altimari, Elisa Gruppioni, Andrea Ardizzoni, Marzia Rossato, Francesco Gelsomino, Pier-Luigi Lollini, Arianna Palladini

Subjects: Get full text

High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer in vitro and in vivo models by Hak Su Kim, Seung-hyun Kwon, Ok Kyung Choi, Taekyu Lim, Taekyu Lim

Subjects: Get full text

Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data by Fabrizio Nelli, Enzo Maria Ruggeri, Antonella Virtuoso, Diana Giannarelli, Armando Raso, Federica Natoni, Gloria Pessina, Daniele Remotti, Mario Giovanni Chilelli, Carlo Signorelli, Agnese Fabbri

Subjects: Get full text

Case report: Multi-organ injuries induced by tislelizumab by Man Yuan, Man Yuan, Ning Han, Ning Han, Li Shu, Libo Yan, Libo Yan, Hong Tang, Hong Tang

Subjects: Get full text

Inhibition of Glutamate‐to‐Glutathione Flux Promotes Tumor Antigen Presentation in Colorectal Cancer Cells by Tao Yu, Kevin Van der Jeught, Haiqi Zhu, Zhuolong Zhou, Samantha Sharma, Sheng Liu, Haniyeh Eyvani, Ka Man So, Naresh Singh, Jia Wang, George E. Sandusky, Yunlong Liu, Mateusz Opyrchal, Sha Cao, Jun Wan, Chi Zhang, Xinna Zhang

Subjects: Get full text

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospectiv... by Gloria Juan-Carpena, Natividad Martínez Banaclocha, Juan Carlos Palazón Cabanes, Maria Niveiro-de Jaime, Isabel Betlloch Mas, Mar Blanes-Martínez

Subjects: Get full text

Catalysts of change: Immunotherapy's frontier in oral oncology by Shyamaladevi Babu, Madhan Krishnan

Subjects: Get full text

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study by Ping Zhou, Bing Liu, Ning Shen, Xiaoting Fan, Shangwei Lu, Zhijuan Kong, Ying Gao, Zhimei Lv, Rong Wang

Subjects: Get full text

Sinonasal small-cell carcinoma combined concurrently with small-cell lung carcinoma: case report and literature review by Rencui Quan, Rencui Quan, Ling Han, Shihai Wu, Xianming Li

Subjects: Get full text

The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literature by Ido Amir, Nir Tsur, Itamar Averbuch, Gideon Bachar, Noga Kurman

Subjects: Get full text

Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer by Yong Zhang, Xiang‐Xiang Chen, Ruo Chen, Ling Li, Qing Ju, Dan Qiu, Yuan Wang, Peng‐Yu Jing, Ning Chang, Min Wang, Jian Zhang, Zhi‐Nan Chen, Ke Wang

Subjects: Get full text

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease by Ayaka Hayashi, Ayaka Hayashi, Hiroto Ishihara, Mayuko Kawabe, Kazuhiko Kato, Kazuhiko Kato, Akio Nakashima, Akio Nakashima, Izumi Yamamoto, Teppei Sakano, Teppei Sakano, Hiroe Kobashi, Makoto Morita, Makoto Morita, Takashi Yokoo, Mitsuyoshi Urashima

Subjects: Get full text

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer by Jie Fu, Jie Fu, Yi-Dan Yan, Xu Wan, Xiao-Fan Sun, Xiao-Fan Sun, Xiu-Mei Ma, Ying-Jie Su

Subjects: Get full text

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA... by Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang

Subjects: Get full text